当前位置: 首页 > 期刊 > 《中国中医药信息杂志》 > 2018年第8期
编号:13285812
护肾(Ⅲ)号胶囊中三七皂苷R1和人参皂苷Rg1在大鼠体内药代动力学研究(1)
http://www.100md.com 2018年8月1日 《中国中医药信息杂志》 2018年第8期
     摘要:目的 建立超高液相色谱串联质谱(UHPLC-MS/MS)测定护肾(Ⅲ)号胶囊给药后大鼠血浆中三七皂苷R1、人参皂苷Rg1含量的方法,并对其药代动力学特征进行研究。方法 SD大鼠灌胃护肾(Ⅲ)号胶囊2 g/kg后按时间点取血,以地高辛为内标,采用UHPLC-MS/MS测定给药不同时点血浆中三七皂苷R1和人参皂苷Rg1浓度,并用DAS2.0软件计算药代动力学参数。结果 三七皂苷R1和人参皂苷Rg1的线性关系良好(r≥0.997 5);日内、日间精密度RSD均小于13.1%,准确度、回收率及稳定性符合生物样品分析要求。大鼠体内三七皂苷R1药代动力学参数:T1/2(7.86±1.69)h,Tmax(4.00±1.04)h,Cmax(0.23±0.05)mg/L;人参皂苷Rg1药代动力学参数:T1/2(4.58±0.95)h,Tmax(6.00±0.00)h,Cmax(0.32±0.03)mg/L。结论 本研究建立的UHPLC-MS/MS分析方法灵敏、准确可靠,适用于护肾(Ⅲ)号胶囊的药代动力学研究。

    关键词:护肾(Ⅲ)号胶囊;超高液相色谱串联质谱;药代动力学

    DOI:10.3969/j.issn.1005-5304.2018.07.017

    中图分类号:R285.5 文献标识码:A 文章编号:1005-5304(2018)07-0071-04

    Abstract: Objective To establish a UHPLC-MS/MS method for the determination of notoginsenoside R1 and ginsenoside Rg1 in rat plasma after oral administration of Hushen (Ⅲ) Capsules; To study its pharmacokinetics. Methods SD rats were given Hushen (Ⅲ) Capsules 2 g/kg and then the blood was collected at time point. Digoxin was used as internal standard. The drug concentrations of notoginsenoside R1 and ginsenoside Rg1 in plasma were determined by UHPLC-MS/MS. And the relative pharmacokinetic parameters were calculated by using DAS2.0 software. Results The linear relationship of notoginsenoside R1 and ginsenoside Rg1 was good (r≥0.997 5). The RSD of intra-day and inter-day precision were less than 13.1%. The results of accuracy, recovery and stability met the requirements for the biology sample analysis. For notoginsenoside R1, the pharmacokinetics parameters T1/2, Tmax, Cmax in the plasma were (7.86±1.69)h, (4.00±1.04)h, (0.23±0.05)mg/L. For ginsenoside Rg1, the pharmacokinetics parameters T1/2, Tmax, Cmax in plasma were (4.58±0.95)h, (6.00±0.00)h, (0.32±0.03)mg/L. Conclusion The established UHPLC-MS/MS method is sensitive, accurate and reliable, and is suitable for the pharmacokinetic study of Hushen (Ⅲ) Capsules.

    Keywords: Hushen (Ⅲ) Capsules; UHPLC-MS/MS; pharmacokinetics

    目前,血尿形成机制尚未完全阐明,通常认为与免疫炎症反应导致肾小球基底膜受损有关,西医治疗往往效果不佳,迁延难愈。肾性血尿属中医学“血证”范畴,中医治疗血尿积累了丰富的临床经验,并取得了较好的疗效[1]。护肾(Ⅲ)号胶囊是张家港市中医医院复方制剂,由白茅根、三七、大黄炭组成,具有清热解毒、滋肾降火功效,临床常用于治疗血尿為主的各种肾病。三七作为方中臣药,具有良好的止血、活血化瘀、消肿止痛作用,辅助君药白茅根治疗血尿诸症。三七总皂苷为三七的主要有效成分,具有抗炎、增强免疫功能的作用。已有研究采用HPLC对护肾(Ⅲ)号胶囊的有效成分进行了含量测定[2]。本研究采用高效、灵敏的超高液相色谱串联质谱(UHPLC-MS/MS)技术对护肾(Ⅲ)号胶囊中三七皂苷R1、人参皂苷Rg1在血浆中的含量进行分析,并对其在大鼠血浆中的药动学特征进行研究,为进一步开展护肾(Ⅲ)号胶囊临床应用研究,明确其作用机制奠定基础。

    1 仪器、试药与动物

    Agilent 1290超高效液相色谱仪;Agilent 6430 LC-MS三重四级杆质谱仪,配有电喷雾化离子源(ESI),MassHunter色谱工作站;AE240电子天平(上海梅特勒-托利多有限公司);MICRO-17R冷冻离心机(美国Thermo公司);WH-2微型旋涡混合仪(上海沪西分析仪器厂);Drict-Q5超纯水机(法国Millipore公司)。, 百拇医药(钱伟 冯星月 陈晓峰 王建平 蒋志涛 余辉)
1 2 3下一页